Biogen BIIB Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $319.5M— | $0-100% | $466.5M-26.5% | $634.8M+164% | $240.5M-9.8% | ||
| $204.4M+2.1% | $200.2M-1.0% | $202.2M+4.1% | $194.3M+6.1% | $183.2M-0.4% | ||
| $84M+40.9% | $59.6M-20.8% | $75.3M+0.5% | $74.9M-7.5% | $81M+7.9% | ||
| $23.6M-85.9% | $166.9M-34.2% | $253.8M+911% | -$31.3M-12.6% | -$27.8M+52.4% | ||
| —— | -$25.68M0.0% | -$25.68M0.0% | -$25.68M0.0% | -$25.68M+53.8% | ||
| -$116.2M-495% | $29.4M+297% | $7.4M-91.8% | $89.9M+245% | -$62M-193% | ||
| -$243.2M-219% | $203.8M-28.7% | $286M+1,671% | -$18.2M+93.9% | -$300.5M-376% | ||
| —— | -$62M0.0% | -$62M0.0% | -$62M0.0% | -$62M-38.8% | ||
| $89M— | —— | $104.4M+375% | $22M-58.9% | $53.5M— | ||
| $18.4M+109% | -$194M+15.4% | -$229.4M+62.0% | -$603.8M-974% | $69.1M+321% | ||
| $19M— | —— | -$500K— | —— | -$40.9M+48.0% | ||
| $20.5M— | —— | $5.6M-57.6% | $13.2M+37.5% | $9.6M— | ||
| $645.5M+26.1% | $511.9M-59.8% | $1.27B+691% | $160.9M-37.9% | $259.3M-65.9% | ||
| $51.2M+16.6% | $43.9M-5.0% | $46.2M+73.7% | $26.6M-28.3% | $37.1M-5.6% | ||
| $748.8M-35.9% | $1.17B— | —— | —— | $0— | ||
| $500K— | —— | $56.6M— | $0— | $0+100% | ||
| $0-100% | $16.3M+208% | $5.3M— | $0-100% | $10M-63.0% | ||
| $200K+101% | -$22.7M+55.3% | -$50.8M-267% | $30.4M+15,100% | $200K-33.3% | ||
| $35M— | —— | —— | —— | $0— | ||
| -$209.5M+83.0% | -$1.23B-3,409% | -$35.1M+38.4% | -$57M-20.5% | -$47.3M-154% | ||
| $55.1M— | —— | —— | —— | $24.3M— | ||
| $11.3M-91.9% | $138.7M-1.8% | $141.2M— | $0-100% | $1.3M— | ||
| -$43.8M+68.0% | -$137M-5.2% | -$130.2M-1,013% | -$11.7M+49.1% | -$23M— | ||
| -$18M-820% | $2.5M— | $0-100% | $68.3M+99.1% | $34.3M+146% | ||
| $392.2M— | —— | $1.11B+1,101% | $92.2M-51.2% | $189M-74.8% | ||
| $107.6M+42.7% | $75.4M+22.6% | $61.5M+17.1% | $52.5M+2.1% | $51.4M+14.5% | ||
| $20.5M— | —— | $5.6M-57.6% | $13.2M+37.5% | $9.6M— | ||
| $4.8M-68.6% | $15.3M— | $0-100% | $7M-4.1% | $7.3M-78.0% | ||
| —— | $13.23M0.0% | $13.23M0.0% | $13.23M0.0% | $13.23M— | ||
| -$28M-47.4% | -$19M+42.9% | -$33.3M-258% | -$9.3M-38.8% | -$6.7M+89.6% | ||
| —— | $21.25M0.0% | $21.25M0.0% | $21.25M0.0% | $21.25M— | ||
| $200K+101% | -$22.7M+55.3% | -$50.8M-267% | $30.4M+15,100% | $200K-33.3% | ||
| $35M— | —— | —— | —— | $0— | ||
| $0-100% | $16.3M+208% | $5.3M— | $0-100% | $10M-63.0% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $11.3M— | —— | $6.2M— | —— | $1.3M— | ||
| $594.3M+27.0% | $468M-61.8% | $1.23B+813% | $134.3M-39.6% | $222.2M-69.2% | ||
| $594.3M+27.0% | $468M-61.8% | $1.23B+813% | $134.3M-39.6% | $222.2M-69.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Biogen generate?
- Biogen (BIIB) generated $2.6B in operating cash flow over the trailing twelve months.
- What is Biogen's free cash flow?
- After $167.9M of capital expenditures, Biogen's free cash flow was $2.4B over the trailing twelve months, down 0.6% year over year.
- Where does Biogen's cash flow data come from?
- Every line is extracted from Biogen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
